On February 8, 2022, Congruence Therapeutics, an innovative biotechnology company, announced the completion of a US$50 million Series A financing.
Congruence Therapeutics is a drug discovery company that is uniquely harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning, AI, and computational chemistry to advance drug discovery. The financing was led by Amplitude Ventures and Fonds de solidarité FTQ, with participation from Lumira Ventures, Investissement Québec, OrbiMed Advisors, Driehaus Capital Management, and other investors.
A Fasken team led by Jonathan Raizenne and Emily Dufresne represented Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures and Investissement Québec in this transaction.
Jurisdiction
- Québec
